J. Cell Biol., Volume 145, Number 3, May 3, 1999 527-538

The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts

Teresa L. Burgess,^* Yi-xin Qian,^* Stephen Kaufman, Brian D. Ring, Gwyneth Van, Charles Capparelli, Michael Kelley,^§ Hailing Hsu, William J. Boyle, Colin R. Dunstan, Sylvia Hu,^* and David L. Lacey

^* Department of Mammalian Cell Molecular Biology,  Department of Pathology, ^§ Department of Protein Chemistry, and  Department of Cell Biology, Amgen Inc., Thousand Oaks, California 91320-1789

Osteoprotegerin (OPG) and OPG-ligand (OPGL) potently inhibit and stimulate, respectively, osteoclast differentiation (Simonet, W.S., D.L. Lacey, C.R. Dunstan, M. Kelley, M.-S. Chang, R. Luethy, H.Q. Nguyen, S. Wooden, L. Bennett, T. Boone, et al. 1997. Cell. 89:309-319; Lacey, D.L., E. Timms, H.-L. Tan, M.J. Kelley, C.R. Dunstan, T. Burgess, R. Elliott, A. Colombero, G. Elliott, S. Scully, et al. 1998. Cell. 93: 165-176), but their effects on mature osteoclasts are not well understood. Using primary cultures of rat osteoclasts on bone slices, we find that OPGL causes approximately sevenfold increase in total bone surface erosion. By scanning electron microscopy, OPGL-treated osteoclasts generate more clusters of lacunae on bone suggesting that multiple, spatially associated cycles of resorption have occurred. However, the size of individual resorption events are unchanged by OPGL treatment. Mechanistically, OPGL binds specifically to mature OCs and rapidly (within 30 min) induces actin ring formation; a marked cytoskeletal rearrangement that necessarily precedes bone resorption. Furthermore, we show that antibodies raised against the OPGL receptor, RANK, also induce actin ring formation. OPGL-treated mice exhibit increases in blood ionized Ca⁺⁺ within 1 h after injections, consistent with immediate OC activation in vivo. Finally, we find that OPG blocks OPGL's effects on both actin ring formation and bone resorption. Together, these findings indicate that, in addition to their effects on OC precursors, OPGL and OPG have profound and direct effects on mature OCs and indicate that the OC receptor, RANK, mediates OPGL's effects.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Kearns, A. E., Khosla, S., Kostenuik, P. J. (2008). Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease. Endocr. Rev. 29: 155-192 [Abstract] [Full Text]  
• Vega, D., Maalouf, N. M., Sakhaee, K. (2007). The Role of Receptor Activator of Nuclear Factor-{kappa}B (RANK)/RANK Ligand/Osteoprotegerin: Clinical Implications. J. Clin. Endocrinol. Metab. 92: 4514-4521 [Abstract] [Full Text]  
• Lopez-Granados, E., Temmerman, S. T., Wu, L., Reynolds, J. C., Follmann, D., Liu, S., Nelson, D. L., Rauch, F., Jain, A. (2007). Osteopenia in X-linked hyper-IgM syndrome reveals a regulatory role for CD40 ligand in osteoclastogenesis. Proc. Natl. Acad. Sci. USA 104: 5056-5061 [Abstract] [Full Text]  
• Mentaverri, R., Yano, S., Chattopadhyay, N., Petit, L., Kifor, O., Kamel, S., Terwilliger, E. F., Brazier, M., Brown, E. M. (2006). The calcium sensing receptor is directly involved in both osteoclast differentiation and apoptosis. FASEB J. 20: 2562-2564 [Abstract] [Full Text]  
• Ramnaraine, M. L., Mathews, W. E., Donohue, J. M., Lynch, C. M., Goblirsch, M. J., Clohisy, D. R. (2006). Osteoclasts Direct Bystander Killing of Bone Cancer.. Cancer Res. 66: 10929-10935 [Abstract] [Full Text]  
• Lipton, A. (2006). Future treatment of bone metastases.. Clin. Cancer Res. 12: 6305s-6308s [Abstract] [Full Text]  
• Pettit, A. R., Walsh, N. C., Manning, C., Goldring, S. R., Gravallese, E. M. (2006). RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology (Oxford) 45: 1068-1076 [Abstract] [Full Text]  
• Yamaguchi, M., Aihara, N., Kojima, T., Kasai, K. (2006). RANKL Increase in Compressed Periodontal Ligament Cells from Root Resorption.. J. Dent. Res. 85: 751-756 [Abstract] [Full Text]  
• Ichikawa, H., Murakami, A., Aggarwal, B. B. (2006). 1'-Acetoxychavicol Acetate Inhibits RANKL-Induced Osteoclastic Differentiation of RAW 264.7 Monocytic Cells by Suppressing Nuclear Factor-{kappa}B Activation. Mol Cancer Res 4: 275-281 [Abstract] [Full Text]  
• Yoshida, H., Okamoto, K., Iwamoto, T., Sakai, E., Kanaoka, K., Hu, J.-P., Shibata, M., Hotokezaka, H., Nishishita, K., Mizuno, A., Kato, Y. (2006). Pepstatin A, an Aspartic Proteinase Inhibitor, Suppresses RANKL-Induced Osteoclast Differentiation.. J Biochem 139: 583-590 [Abstract] [Full Text]  
• Xu, D., Wang, S., Liu, W., Liu, J., Feng, X. (2006). A Novel Receptor Activator of NF-{kappa}B (RANK) Cytoplasmic Motif Plays an Essential Role in Osteoclastogenesis by Committing Macrophages to the Osteoclast Lineage. J. Biol. Chem. 281: 4678-4690 [Abstract] [Full Text]  
• McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., Lain, D., Kivitz, A. J., Holloway, D. L., Zhang, C., Peterson, M. C., Bekker, P. J., the AMG 162 Bone Loss Study Group, (2006). Denosumab in postmenopausal women with low bone mineral density.. NEJM 354: 821-831 [Abstract] [Full Text]  
• Body, J.-J., Facon, T., Coleman, R. E., Lipton, A., Geurs, F., Fan, M., Holloway, D., Peterson, M. C., Bekker, P. J. (2006). A Study of the Biological Receptor Activator of Nuclear Factor-{kappa}B Ligand Inhibitor, Denosumab, in Patients with Multiple Myeloma or Bone Metastases from Breast Cancer. Clin. Cancer Res. 12: 1221-1228 [Abstract] [Full Text]  
• Liu, W., Wang, S., Wei, S., Sun, L., Feng, X. (2005). Receptor Activator of NF-{kappa}B (RANK) Cytoplasmic Motif, 369PFQEP373, Plays a Predominant Role in Osteoclast Survival in Part by Activating Akt/PKB and Its Downstream Effector AFX/FOXO4. J. Biol. Chem. 280: 43064-43072 [Abstract] [Full Text]  
• Boissy, P., Andersen, T. L., Abdallah, B. M., Kassem, M., Plesner, T., Delaisse, J.-M. (2005). Resveratrol Inhibits Myeloma Cell Growth, Prevents Osteoclast Formation, and Promotes Osteoblast Differentiation. Cancer Res. 65: 9943-9952 [Abstract] [Full Text]  
• Rogers, A., Eastell, R. (2005). Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor {kappa}B Ligand: Clinical Utility in Metabolic Bone Disease Assessment. J. Clin. Endocrinol. Metab. 90: 6323-6331 [Abstract] [Full Text]  
• Frick, K. K., LaPlante, K., Bushinsky, D. A. (2005). RANK ligand and TNF-{alpha} mediate acid-induced bone calcium efflux in vitro. Am. J. Physiol. Renal Physiol. 289: F1005-F1011 [Abstract] [Full Text]  
• Chellaiah, M. A. (2005). Regulation of Actin Ring Formation by Rho GTPases in Osteoclasts. J. Biol. Chem. 280: 32930-32943 [Abstract] [Full Text]  
• Xie, F., Wu, C.-F., Lai, W.-P., Yang, X.-j., Cheung, P.-Y., Yao, X.-S., Leung, P.-C., Wong, M.-S. (2005). The osteoprotective effect of Herba epimedii (HEP) extract in vivo and in vitro. Evid Based Complement Alternat Med 2: 353-361 [Abstract] [Full Text]  
• Morony, S., Warmington, K., Adamu, S., Asuncion, F., Geng, Z., Grisanti, M., Tan, H. L., Capparelli, C., Starnes, C., Weimann, B., Dunstan, C. R., Kostenuik, P. J. (2005). The Inhibition of RANKL Causes Greater Suppression of Bone Resorption and Hypercalcemia Compared with Bisphosphonates in Two Models of Humoral Hypercalcemia of Malignancy. Endocrinology 146: 3235-3243 [Abstract] [Full Text]  
• Mangashetti, L. S., Khapli, S. M., Wani, M. R. (2005). IL-4 Inhibits Bone-Resorbing Activity of Mature Osteoclasts by Affecting NF-{kappa}B and Ca2+ Signaling. J. Immunol. 175: 917-925 [Abstract] [Full Text]  
• Shaarawy, M., Zaki, S., Ramzi, A.-M., Salem, M. E., El-Minawi, A. M. (2005). Feto-maternal Bone Remodeling in Normal Pregnancy and Preeclampsia. Reproductive Sciences 12: 343-348 [Abstract]  
• Ito, M., Matsuka, N., Izuka, M., Haito, S., Sakai, Y., Nakamura, R., Segawa, H., Kuwahata, M., Yamamoto, H., Pike, W. J., Miyamoto, K.-i. (2005). Characterization of inorganic phosphate transport in osteoclast-like cells. Am. J. Physiol. Cell Physiol. 288: C921-C931 [Abstract] [Full Text]  
• Byrne, F R, Morony, S, Warmington, K, Geng, Z, Brown, H L, Flores, S A, Fiorino, M, Yin, S L, Hill, D, Porkess, V, Duryea, D, Pretorius, J K, Adamu, S, Manuokian, R, Danilenko, D M, Sarosi, I, Lacey, D L, Kostenuik, P J, Senaldi, G (2005). CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. Gut 54: 78-86 [Abstract] [Full Text]  
• Tolar, J., Teitelbaum, S. L., Orchard, P. J. (2004). Osteopetrosis. NEJM 351: 2839-2849 [Full Text]  
• Liu, W., Xu, D., Yang, H., Xu, H., Shi, Z., Cao, X., Takeshita, S., Liu, J., Teale, M., Feng, X. (2004). Functional Identification of Three Receptor Activator of NF-{kappa}B Cytoplasmic Motifs Mediating Osteoclast Differentiation and Function. J. Biol. Chem. 279: 54759-54769 [Abstract] [Full Text]  
• Cheng, X., Kinosaki, M., Takami, M., Choi, Y., Zhang, H., Murali, R. (2004). Disabling of Receptor Activator of Nuclear Factor-{kappa}B (RANK) Receptor Complex by Novel Osteoprotegerin-like Peptidomimetics Restores Bone Loss in Vivo. J. Biol. Chem. 279: 8269-8277 [Abstract] [Full Text]  
• Lund, R. J., Davies, M. R., Brown, A. J., Hruska, K. A. (2004). Successful Treatment of an Adynamic Bone Disorder with Bone Morphogenetic Protein-7 in a Renal Ablation Model. J. Am. Soc. Nephrol. 15: 359-369 [Abstract] [Full Text]  
• Skoumal, M, Kolarz, G, Woloszczuk, W, Hawa, G, Klingler, A (2004). Serum osteoprotegerin but not receptor activator of NF-{kappa}B ligand correlates with Larsen score in rheumatoid arthritis. Ann Rheum Dis 63: 216-217 [Full Text]  
• Henriksen, K., Karsdal, M., Delaisse, J.-M., Engsig, M. T. (2003). RANKL and Vascular Endothelial Growth Factor (VEGF) Induce Osteoclast Chemotaxis through an ERK1/2-dependent Mechanism. J. Biol. Chem. 278: 48745-48753 [Abstract] [Full Text]  
• Ikeda, T., Kasai, M., Suzuki, J., Kuroyama, H., Seki, S., Utsuyama, M., Hirokawa, K. (2003). Multimerization of the Receptor Activator of Nuclear Factor-{kappa}B Ligand (RANKL) Isoforms and Regulation of Osteoclastogenesis. J. Biol. Chem. 278: 47217-47222 [Abstract] [Full Text]  
• Grimaud, E., Soubigou, L., Couillaud, S., Coipeau, P., Moreau, A., Passuti, N., Gouin, F., Redini, F., Heymann, D. (2003). Receptor Activator of Nuclear Factor {kappa}B Ligand (RANKL)/Osteoprotegerin (OPG) Ratio Is Increased in Severe Osteolysis. Am. J. Pathol. 163: 2021-2031 [Abstract] [Full Text]  
• Farrugia, A. N., Atkins, G. J., To, L. B., Pan, B., Horvath, N., Kostakis, P., Findlay, D. M., Bardy, P., Zannettino, A. C. W. (2003). Receptor Activator of Nuclear Factor-{kappa}B Ligand Expression by Human Myeloma Cells Mediates Osteoclast Formation in Vitro and Correlates with Bone Destruction in Vivo. Cancer Res. 63: 5438-5445 [Abstract] [Full Text]  
• Sohara, Y., Shimada, H., Scadeng, M., Pollack, H., Yamada, S., Ye, W., Reynolds, C. P., DeClerck, Y. A. (2003). Lytic Bone Lesions in Human Neuroblastoma Xenograft Involve Osteoclast Recruitment and Are Inhibited by Bisphosphonate. Cancer Res. 63: 3026-3031 [Abstract] [Full Text]  
• Yonou, H., Kanomata, N., Goya, M., Kamijo, T., Yokose, T., Hasebe, T., Nagai, K., Hatano, T., Ogawa, Y., Ochiai, A. (2003). Osteoprotegerin/Osteoclastogenesis Inhibitory Factor Decreases Human Prostate Cancer Burden in Human Adult Bone Implanted into Nonobese Diabetic/Severe Combined Immunodeficient Mice. Cancer Res. 63: 2096-2102 [Abstract] [Full Text]  
• Destaing, O., Saltel, F., Geminard, J.-C., Jurdic, P., Bard, F. (2003). Podosomes Display Actin Turnover and Dynamic Self-Organization in Osteoclasts Expressing Actin-Green Fluorescent Protein. Mol. Biol. Cell 14: 407-416 [Abstract] [Full Text]  
• Gurlek, A., Pittelkow, M. R., Kumar, R. (2002). Modulation of Growth Factor/Cytokine Synthesis and Signaling by 1{alpha},25-Dihydroxyvitamin D3: Implications in Cell Growth and Differentiation. Endocr. Rev. 23: 763-786 [Abstract] [Full Text]  
• Crotti, T N, Smith, M D, Weedon, H, Ahern, M J, Findlay, D M, Kraan, M, Tak, P P, Haynes, D R (2002). Receptor activator NF-{kappa}B ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 61: 1047-1054 [Abstract] [Full Text]  
• Armstrong, A. P., Tometsko, M. E., Glaccum, M., Sutherland, C. L., Cosman, D., Dougall, W. C. (2002). A RANK/TRAF6-dependent Signal Transduction Pathway Is Essential for Osteoclast Cytoskeletal Organization and Resorptive Function. J. Biol. Chem. 277: 44347-44356 [Abstract] [Full Text]  
• Hirayama, T., Danks, L., Sabokbar, A., Athanasou, N. A. (2002). Osteoclast formation and activity in the pathogenesis of osteoporosis in rheumatoid arthritis. Rheumatology (Oxford) 41: 1232-1239 [Abstract] [Full Text]  
• Jones, D H., Kong, Y-Y, Penninger, J M (2002). Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis 61: ii32-39 [Abstract] [Full Text]  
• Gravallese, E M (2002). Bone destruction in arthritis. Ann Rheum Dis 61: ii84-86 [Abstract] [Full Text]  
• Romas, E., Sims, N. A., Hards, D. K., Lindsay, M., Quinn, J. W.M., Ryan, P. F.J., Dunstan, C. R., Martin, T. J., Gillespie, M. T. (2002). Osteoprotegerin Reduces Osteoclast Numbers and Prevents Bone Erosion in Collagen-Induced Arthritis. Am. J. Pathol. 161: 1419-1427 [Abstract] [Full Text]  
• Arko, B., Prezelj, J., Komel, R., Kocijancic, A., Hudler, P., Marc, J. (2002). Sequence Variations in the Osteoprotegerin Gene Promoter in Patients with Postmenopausal Osteoporosis. J. Clin. Endocrinol. Metab. 87: 4080-4084 [Abstract] [Full Text]  
• Pfeilschifter, J., Koditz, R., Pfohl, M., Schatz, H. (2002). Changes in Proinflammatory Cytokine Activity after Menopause. Endocr. Rev. 23: 90-119 [Abstract] [Full Text]  
• Kim, N., Takami, M., Rho, J., Josien, R., Choi, Y. (2002). A Novel Member of the Leukocyte Receptor Complex Regulates Osteoclast Differentiation. J. Exp. Med. 195: 201-209 [Abstract] [Full Text]  
• Giuliani, N., Bataille, R., Mancini, C., Lazzaretti, M., Barille, S. (2001). Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98: 3527-3533 [Abstract] [Full Text]  
• Croucher, P. I., Shipman, C. M., Lippitt, J., Perry, M., Asosingh, K., Hijzen, A., Brabbs, A. C., van Beek, E. J. R., Holen, I., Skerry, T. M., Dunstan, C. R., Russell, G. R., Van Camp, B., Vanderkerken, K. (2001). Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98: 3534-3540 [Abstract] [Full Text]  
• Feige, U (2001). Osteoprotegerin. Ann Rheum Dis 60: iii81-84 [Full Text]  
• Kostenuik, P. J., Capparelli, C., Morony, S., Adamu, S., Shimamoto, G., Shen, V., Lacey, D. L., Dunstan, C. R. (2001). OPG and PTH-(1-34) Have Additive Effects on Bone Density and Mechanical Strength in Osteopenic Ovariectomized Rats. Endocrinology 142: 4295-4304 [Abstract] [Full Text]  
• Yamagishi, T., Otsuka, E., Hagiwara, H. (2001). Reciprocal Control of Expression of mRNAs for Osteoclast Differentiation Factor and OPG in Osteogenic Stromal Cells by Genistein: Evidence for the Involvement of Topoisomerase II in Osteoclastogenesis. Endocrinology 142: 3632-3637 [Abstract] [Full Text]  
• Lee, Z. H., Kwack, K., Kim, K. K., Lee, S. H., Kim, H.-H. (2001). Activation of c-Jun N-Terminal Kinase and Activator Protein 1 by Receptor Activator of Nuclear Factor kappa B. Mol. Pharmacol. 58: 1536-1545 [Abstract] [Full Text]  
• Chen, D., Sarikaya, N. A., Gunn, H., Martin, S. W., Young, J. D. (2001). ELISA Methodology for Detection of Modified Osteoprotegerin in Clinical Studies. Clin. Chem. 47: 747-749 [Full Text]  
• Oyajobi, B. O., Anderson, D. M., Traianedes, K., Williams, P. J., Yoneda, T., Mundy, G. R. (2001). Therapeutic Efficacy of a Soluble Receptor Activator of Nuclear Factor {{kappa}}B-IgG Fc Fusion Protein in Suppressing Bone Resorption and Hypercalcemia in a Model of Humoral Hypercalcemia of Malignancy. Cancer Res. 61: 2572-2578 [Abstract] [Full Text]  
• Kikuchi, T., Matsuguchi, T., Tsuboi, N., Mitani, A., Tanaka, S., Matsuoka, M., Yamamoto, G., Hishikawa, T., Noguchi, T., Yoshikai, Y. (2001). Gene Expression of Osteoclast Differentiation Factor Is Induced by Lipopolysaccharide in Mouse Osteoblasts Via Toll-Like Receptors. J. Immunol. 166: 3574-3579 [Abstract] [Full Text]  
• Gori, F., Hofbauer, L. C., Dunstan, C. R., Spelsberg, T. C., Khosla, S., Riggs, B. L. (2000). The Expression of Osteoprotegerin and RANK Ligand and the Support of Osteoclast Formation by Stromal-Osteoblast Lineage Cells Is Developmentally Regulated. Endocrinology 141: 4768-4776 [Abstract] [Full Text]  
• Teitelbaum, S. L. (2000). Bone Resorption by Osteoclasts. Science 289: 1504-1508 [Abstract] [Full Text]  
• Lacey, D. L., Tan, H. L., Lu, J., Kaufman, S., Van, G., Qiu, W., Rattan, A., Scully, S., Fletcher, F., Juan, T., Kelley, M., Burgess, T. L., Boyle, W. J., Polverino, A. J. (2000). Osteoprotegerin Ligand Modulates Murine Osteoclast Survival in Vitro and in Vivo. Am. J. Pathol. 157: 435-448 [Abstract] [Full Text]  
• Hofbauer, L. C., Heufelder, A. E. (2000). The Role of Receptor Activator of Nuclear Factor-{kappa}B Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases. J. Clin. Endocrinol. Metab. 85: 2355-2363 [Full Text]  
• Manolagas, S. C. (2000). Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis. Endocr. Rev. 21: 115-137 [Abstract] [Full Text]  
• Capparelli, C., Kostenuik, P. J., Morony, S., Starnes, C., Weimann, B., Van, G., Scully, S., Qi, M., Lacey, D. L., Dunstan, C. R. (2000). Osteoprotegerin Prevents and Reverses Hypercalcemia in a Murine Model of Humoral Hypercalcemia of Malignancy. Cancer Res. 60: 783-787 [Abstract] [Full Text]  
• Kobayashi, K., Takahashi, N., Jimi, E., Udagawa, N., Takami, M., Kotake, S., Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Morinaga, T., Higashio, K., Martin, T. J., Suda, T. (2000). Tumor Necrosis Factor {alpha} Stimulates Osteoclast Differentiation by a Mechanism Independent of the ODF/RANKL-RANK Interaction. J. Exp. Med. 191: 275-286 [Abstract] [Full Text]  
• Karsenty, G. (1999). The genetic transformation of bone biology. Genes Dev. 13: 3037-3051 [Full Text]  
• Manolagas, S. C. (1999). Editorial: Cell Number Versus Cell Vigor--What Really Matters to a Regenerating Skeleton?. Endocrinology 140: 4377-4381 [Full Text]  
• Zhou, H., Kartsogiannis, V., Hu, Y. S., Elliott, J., Quinn, J. M. W., McKinstry, W. J., Gillespie, M. T., Ng, K. W. (2001). A Novel Osteoblast-derived C-type Lectin That Inhibits Osteoclast Formation. J. Biol. Chem. 276: 14916-14923 [Abstract] [Full Text]  
• Thirunavukkarasu, K., Miles, R. R., Halladay, D. L., Yang, X., Galvin, R. J. S., Chandrasekhar, S., Martin, T. J., Onyia, J. E. (2001). Stimulation of Osteoprotegerin (OPG) Gene Expression by Transforming Growth Factor-beta (TGF-beta ). MAPPING OF THE OPG PROMOTER REGION THAT MEDIATES TGF-beta EFFECTS. J. Biol. Chem. 276: 36241-36250 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents